【摘要】 目的:观察急性白血病(AL)血清中可溶性细胞间黏附分子-(1sICAM-1)和可溶性血管细胞间黏附分子-(1sVCAM-1)的表达水平及其临床意义。方法:在60例初诊AL,以及治疗后达到完全缓解(CR)的16例患者中采集外周血分离出血清。采用酶联免疫吸附试验(ELISA)方法检测sICAM-1和sVCAM-1的水平,并探讨其与临床特征之间的关系。结果:在初诊AL患者中sICAM-1和sVCAM-1的水平明显高于CR组和正常对照组,CR组sICAM-1与sVCAM-1水平和正常对照组无显著差异(P<0.01,P<0.01)。在初诊AL中,能够达到CR的患者其sICAM-1与sVCAM-1水平要低于未达到CR患者(P<0.05,P<0.05)。在高白细胞白血病(WBC>100×109/L)中,sICAM-1和sVCAM-1的水平和其他非高白细胞白血病无差异(P=0.059,P=0.146)。具有良好核型组和其对应组之间sICAM-1和sVCAM-1无统计学差异(P=0.262,P=0.558)。sICAM-1和sVCAM-1不同水平的患者生存期无差异。结论:AL血清sICAM-1和sVCAM-1表达水平异常且影响疗效,但无预后意义。更多还原

【Abstract】 Objective:To investigate the levels of soluble intercellular adhesion molecule-1(sICAM-1) and soluble vascular cell adhesion molecule-1(sVCAM-1) in serum of patients with acute leukemia(AL) and evaluate their clinical significance. Methods: Sixty untreated patients with AL(39 with acute non-lymphoid leukemia, 21 with acute lymphoid leukemia) were included in this study. Serum levels of sICAM-1 and sVCAM-1 were determined using commercially available immunoassays(ELISA). In addition, twelve healthy volunteers were studied as control. Results:Serum sICAM-1 and sVCAM-1 levels were significantly higher in untreated patients than those in control and the complete remission group(P < 0.001, P < 0.001). In initial diagnosed patients with AL, the patient who achieved CR showed lower levels of sICAM-1和sVCAM-1 than those without CR(P < 0.05, P < 0.05). While the difference of the serum levels of sICAM-1 and sVCAM-1 between CR group with control group was not significant. The patients with different levels of sICAM-1 or sVCAM-1 showed no statistical difference in overall survival. Conclusion:Serum levels of sICAM-1 and sVCAM-1 in patients with AL are abnormal which influence the therapeutic efficiency but had no prognostic significance.更多还原